A randomized open-label multicenter phase III trial of Melphalan and Dexamethasone (MDex) versus Bortezomib, Melphalan and Dexamethasone (BMDex) for untreated patients with systemic light-chain (AL) amyloidosis
- Registry ID
- EUCTR2010-022395-31
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE3
- Sponsor
- E.M.N. - EUROPEAN MYELOMA NETWORK
- Start date
- 2010-10-07
- Last update
- 2026-08-16
Conditions
- AL amyloidosis
- Systemic light-chain (AL) amyloidosis
- Primary Systemic (AL) Amyloidosis
Summary
To compare the hematologic response after 3 cycles of therapy.
Locations
- , , Italy
- , , Germany
- , , Spain
- , , Greece
- , , Sweden
- , , Denmark
- , , Czechia
- , , UK
View on source registry